|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Antihypertensives - Can Manufacturers Maintain Value?
Datamonitor, Oct 2004, Pages: 89
The antihypertensive market accounted for almost $30 billion in the seven major markets in 2003 and this value is set to rise as prevalence increases.
The increasing use of multiple drug therapy and the falling use of older drug classes in the absence of specific compelling indications is continuing to drive sales of the largest classes and will provide a growing market for an new entrants.
Scope of report:
Country specific event-driven sales forecasts for the period 2004-14 for the US, Japan, France, Germany, Italy, Spain and the UK and Global overview
Patient potential and prescribing trends overview of the antihypertensive market based on historical sales data and future key events
Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and class switching
Case studies presenting the effect of launch strategy into the ARB market, additional indications and outcome-based clinical trials
Highlights:
The antihypertensive market has seen continuing growth driven by increasing global prevalence and more aggressive treatment allow it to grow to a 30 billion dollar market in 2003, these trends are set to continue but as governments seek to reduce healthcare spending antihypertensives will come under scrutiny as a source of savings.
Patent expiries of major brands will be the leading events shaping the future of the antihypertensives market in the period until 2014, the global market leader, Norvasc, and the fastest growing class, ARBs, will both face genericization during this period, driving down costs and encouraging switching from older classes.
Datamonitor forecasts that combination products will drive sales in the ARB class once key product patent expiries force allow genericization of plain formulation products, however physicians are often cynical of manufacturers motives for producing these combinations and the benefits to patients must be highlighted to maintain physician confidence.
Reasons to Purchase:
Identify possible future strategy to maximize product potential and minimize risks for the ARB market
View independent, event-driven forecasts for key antihypertensive products and classes across the seven major markets
Assess the impact of the Norvasc patent expiry on the market and identify which CCBs, if any, could benefit from the increased competition
Customers who bought this item also bought
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
Forecast Insight: Antihypertensives - Key Patent Expiries Prevent Market Growth
Forecast Insight: Antihypertensives New fixed dose combinations unable to stem the tide of patent expiries
Commercial Insight: Cytotoxic Therapy Cancer Brands - Looming Patent Expiries Limit Market Growth
Commercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products
Generic Cancer Market - New Legislation and a Wave of Patent Expiries to Transform the Market
Report on Antihypertensive Drug Market
Antihypertensives - Two Years to Shape the Market?
Commercial Insight: Antihypertensives - New Challenges for a Maturing Market
Stakeholder Opinions: Bone Metastases - Impending Patent Expiries May Help Make or Break Newer Agents
Market Dynamics 2000: Allergic Rhinitis: Effects of Major Patent Expiries On An Expanding Market
Commercial Insight: Cardiovascular Market Overview - Raft of Patent Expires Threaten Blockbusters
|
|
|
|
